The United Kingdom and the United States have agreed to a key commercial pact that will guarantee zero import taxes on UK medicine shipments being sold in the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost spending on drugs through the public health system. This move secures that import taxes on these key products will remain at nothing for a period of three years.
This development comes after earlier warnings to dramatically increase tariffs on patented drug imports, with potential rates mentioned reaching 100%.
"This agreement with the Britain bolsters the global environment for innovative medicines and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement declared.
Commercial Significance
Pharmaceuticals represent one of the Britain's largest export categories to the US, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Statistics show that in the year prior to last September, the UK exported medicines worth £11.1bn to the US. This figure made up nearly one-fifth of British export trade in that period.
"This guarantee protects jobs, increases investment and paves the way for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The deal involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be capped at 15%. Last year, refunds topped twenty percent.
Recent Tensions
The deal comes amid a long-running row between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were heightened by assertions that US customers were paying several times more for the identical medicines than consumers in the other developed nations.
In recent months, several large drug company projects in the UK have been halted or abandoned, while substantial investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the past decade.
